Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 134 posts
Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 20, 2019 | Videos

Will innovative contracts gain momentum in the future?

US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers whether they think that innovative contracts will gain momentum in the future.

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 20, 2019 | Research posters

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?

ISPOR International 2019: CBPartners presented a poster to describe what it means to be cost-effective in an analysis of three different markets with HTA bodies that use CE analysis.

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: Value-Based Contracts – When and How Can They Actually Work?

ISPOR International 2019: CBPartners presented a poster which investigates how and when value-based-contracts (VBCs) can work effectively.

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: The Importance of the Overall Survival Endpoint in EU HTA Decision-Making

ISPOR International 2019: CBPartners presented a research poster to describe the importance of the overall survival (OS) endpoint in EU HTA decision-making.

ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: The Rising Patient Voice – Changing Value of PRO and QoL Metrics

ISPOR International 2019: CBPartners presented a reseach poster about the changing value of patient-reported outcome (PRO) and quality of life (QoL) metrics.